Detail akcie Axsome Therapeutics online

Business Summary: Axsome Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for people living with central nervous system (CNS) conditions. The Company's commercial products include Auvelity, Sunosi and Symbravo. It is also advancing a diversified, late-stage pipeline of product candidates for serious neurological and psychiatric conditions, which include AXS-05, AXS-12, AXS-14 and AXS-17. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. Symbravo (meloxicam and rizatriptan, 20 mg/10mg tablets) is an oral, single-dose medicine approved for the acute treatment of migraine with or without aura in adults.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Axsome Therapeutics Inc revenues increased 66% to $442.5M. Net loss decreased 27% to $154.6M. Revenues reflect Auvelitv segment increase from $80.4M to $352M, Sunosi segment increase from $23.4M to $84.6M, United States segment increase from $102.8M to $435M, Outside of the United States segment increase from $926K to $7.5M.